Insuline vs Glucagon: A Technical Pros and Cons Breakdown
Abstract: Insulin and glucagon, key peptide hormones, exhibit opposing metabolic roles: insulin lowers blood glucose via cellular uptake, while glucagon raises it through glycogenolysis. Technically, insulin offers superior glycemic control but risks hypoglycemia; glucagon’s advantage lies in emergency hyperglycemia correction. Market trends show rising demand for analog insulins (e.g., Novo Nordisk’s Tresiba) and stable glucagon formulations (e.g., Eli Lilly’s Baqsimi). Product comparisons highlight insulin’s broader therapeutic range (Type 1/2 diabetes) versus glucagon’s niche (severe hypoglycemia). Regulatory certifications (FDA, EMA) and cold-chain logistics (2–8°C) are critical. Industry data projects 8.5% CAGR for peptide diabetes therapies through 2030, favoring biosimilar competition.